X‑Chem and Abilita Bio Announce a Joint Research Collaboration
(XChem), and Abilita Bio, Inc. (Abilita), both privately held biotechnology companies, announce today a joint research collaboration that will leverage the synergy between each companyβs platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCR) and ion channel targets.
Why X‑Chem
English French Our Culture X-Chem has been pioneering drug discovery since 2009, offering pharma and biotech partners the best chance...
Working at X‑Chem
Our Culture X-Chem has been pioneering drug discovery since 2009, offering pharma and biotech partners the best chance for success...
X‑Chem Provides Year-End Update on Partnership Achievements
X-Chem, Inc. announces that it has licensed its 40th drug discovery program to an undisclosed large Pharma partner, granting exclusive rights to novel small molecules that interact with the partnerβs therapeutic target of interest.
X‑Chem and Kymera Expand Existing Partnership
WALTHAM, Mass.; Jan. 31, 2023 β X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the...
BioDuro-Sundia and X‑Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs
Shanghai, August 8 2022 – BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and...
LEO Pharma and X‑Chem Enter Into Discovery Research Agreement
Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications BALLERUP, Denmark, and WALTHAM, Mass., US;...
Refining covalent warhead reactivity: A new look at GSH reactivity assays
If the bond is forever, it needs to be safe. Covalent drugs have proved to be successful therapies for various...
DELability
A quick, comprehensive review of DEL screening suitability As DNA-encoded libraries (DELs) become standard for hit identification, there remain questions...
X‑Chem and the SGC are pioneering crowd-sourced AI advancements by making DEL screening data publicΒ
Artificial intelligence (AI) is now recognized as an indispensable component of the modern drug discovery tool kit, applied at all...